Ignite Creation Date:
2024-05-06 @ 8:26 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06384352
Status:
RECRUITING
Last Update Posted:
2024-05-10
First Post:
2024-03-26
Brief Title:
A Phase I Study to Evaluate the SafetyTolerability Pharmacokinetics and Efficacy of YL211 in Patients With Advanced Solid Tumors
Sponsor:
MediLink Therapeutics Suzhou Co Ltd
Organization:
MediLink Therapeutics Suzhou Co Ltd
Organization Data
Organization:
MediLink Therapeutics Suzhou Co Ltd
Class:
INDUSTRY
Study ID:
YL211-INT-101-01
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
MediLink Therapeutics Suzhou Co Ltd
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Hoffmann-La Roche | INDUSTRY |